Nottingham-based Sygnature Discovery, the independent integrated drug discovery and pre-clinical services provider, has acquired XenoGesis.
The acquisition significantly expands Sygnature’s DMPK capabilities and expertise, with XenoGesis the UK’s largest independent laboratory-based CRO specialising in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation.
Dr Simon Hirst, CEO and Founder at Sygnature, said: “Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process, and we recognise the central role that DMPK plays in that journey.
“Sygnature is not growing for the sake of growing. We believe that truly integrated drug discovery is the best possible way forward in bringing novel efficacious drug candidates to man; that having teams working together across every discipline involved in a research project, sharing ideas and resolving challenges, will produce the sparks of innovation and high-quality science needed to enable success.
“We have always had tremendous respect for the work that XenoGesis does, and have a strong history of collaboration with them over the years. We are thrilled at this opportunity to build on the capabilities of both companies and enrich our service-offering going forward together.”
Both businesses are located at BioCity in Nottingham.
Dr Richard Weaver, CEO and Founder at XenoGesis added: “Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations. From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers.
“Therefore, this step feels like a very natural one, and we are very excited about what we can accomplish together in helping accelerate our customers’ projects towards the clinic. My team and I are looking forward to joining forces with Sygnature.”